Inflammation levels in patients with alcohol and substance use disorders
Abstract
Purpose: The aim of this study was to analyse the inflammation indicators of two patients, which were diagnosed with alcohol use disorder(AUD), and substance use disorder(SUD), with each other as well as with the healthy control group.
Materials and Methods: A group of 159 people (100 patient, 59 healthy control) have been included in the study. All participants have been applied a demographical data form and laboratory parameters have been evaluated with complete blood cell count.
Results: Among the patients diagnosed with SUD, 24 (%48) cannabis while 26 (%52) used synthetic cannabinoid. In both patient groups the values of haemoglobin, haematocrit, RDW-standard deviation value (RDW-SD), main platelet volume (MPV) was tested to be higher than that of the healthy control groups. While the platelet value of AUD patients was lower than the two other groups, erythrocyte value of SUD patients was higher than the two other groups.
Conclusion: Some inflammatory parameters could affect ASUD pathophysiology. In addition, complications such as spontaneous bleeding and susceptibility to infectious diseases that may occur due to changes in these parameters should be kept in mind during both in treatment planning and the development of symptoms.
Keywords
Alcohol use disorder , cannabis , synthetic cannabinoid , inflammation
Kaynakça
- Referans1. Harris MG, Bharat C, Glantz MD, Sampson NA, Al Hamzawi A, Alonso J, et al. World Health Organization's World Mental Health Surveys collaborators. Cross‐national patterns of substance use disorder treatment and associations with mental disorder comorbidity in the WHO World Mental Health Surveys. Addiction. 2019; 114(8): 1446-1459.
- Referans 2. Degenhardt L, Glantz M, Evans Lacko S, Sadikova E, Sampson N, Thornicroft G, et al. Estimating treatment coverage for people with substance use disorders: an analysis of data from the World Mental Health Surveys. World Psychiatry. 2017; 16(3): 299-307.
- Referans 3. World Health Organization and Research for International Tobacco Control. WHO report on the global burden of disease: 2008 update. World Health Organization, 2008.
- Referans 4. Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T. The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010. PloS one. 2015; 10(2): e0116820.
- Referans 5. Prom-Wormley EC, Ebejer J, Dick DM, Bowers MS. The genetic epidemiology of substance use disorder: a review. Drug Alcohol Depend. 2017; 180: 241-259.
- Referans 6. Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F. Imaging dopamine’s role in drug abuse and addiction. Neuropharmacol. 2009; 56:3-8.
- Referans 7. Müller N. Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations. Schizophr Bull. 2018; 44(5): 973-982.
- Referans 8. Muneer A. Bipolar disorder: role of inflammation and the development of disease biomarkers. Psychiatry Investig. 2016; 13: 18-33.
- Referans 9. Michopoulos V, Powers A, Gillespie CF, Ressler KJ, Jovanovic T. Inflammation in fear- and anxiety-based disorders: PTSD, GAD, and beyond. Neuropsychopharmacol. 2017; 42: 254-270.
- Referans 10. Sunbul M, Gerin F, Durmus E, Kivrak T, Sari I, Tigen K, et al. Neutrophil to lymphocyte and platelet to lymphocyte ratio in patients with dipper versus non-dipper hypertension. Clin Exp Hypertens. 2014; 36:217-221.
